MCT Enteral Feeding to Reduce Chyle Leak After Oesophagectomy

Recruiting N/A Interventional Study
Oesphageal Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Prevention
Participants needed
160 (estimated)
Sponsor
Royal College of Surgeons, Ireland · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Chyle leak (chylothorax) is a recognised complication following minimally invasive oesophagectomy for oesophageal cancer and may result in prolonged hospital stay, nutritional compromise, and need for additional interventions. Medium-chain triglyceride (MCT) feeds reduce lymphatic flow as they are absorbed directly via the portal circulation rather than through the thoracic duct. While MCT feeds …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Diagnosis of oesophageal cancer (adenocarcinoma or squamous cell carcinoma) * Planned minimally invasive or robotic-assisted oesophagectomy (MIO or RAMIO) with curative intent * Placement of feeding jejunostomy at or prior to oesophagectomy * Able to provide w…
Contacts

Prof jarlath Bolger, MB, BCh, BAO, MCh, FRCSI

018093000

jarbolger@rcsi.com

CONTACT